Clinical trials: Kidney (Renal Cell) Cancer
Hepatitis C, Renal Cell Carcinoma
Association Between Hepatitis C Infection and Renal Cell Carcinoma
The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered…
- Conditions
- Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT01405183
- Testing
- Hepatitis C testing
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Henry Ford Health System
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-II
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-II (NCT03655821)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Radboud University Medical Center
Renal Cell Carcinoma
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart) in IL-2 eligible clear cell metastatic…
- Trial name
- NCT02989714
- Testing
- Interleukin-2, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Renal Cell Carcinoma (mRCC)
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line…
- Trial name
- ADONIS (NCT02184416)
- Testing
- observational
- Where
- 110 sites in Austria, Belgium and 6 more
- Volunteers
- 554 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
- Trial name
- NCT00975806
- Testing
- Lenalidomide, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer).
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-201 (NCT03219333)
- Testing
- Enfortumab vedotin
- Where
- 81 sites in United States, France and 6 more
- Volunteers
- 219 people
- Sponsor
- Astellas Pharma Inc
Kidney Neoplasms
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
Background: Some patients with advanced kidney cancer have immune cells that can recognize and kill their cancer, but the cells are not active enough or numerous enough to accomplish this on their own.
- Trial name
- NCT00091611
- Testing
- IL-2 (interleukin-2), OKT3, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells.
- Trial name
- NCT00002737
- Testing
- recombinant interferon alfa, chemotherapy, isotretinoin
- Where
- 27 sites in Belgium, Hungary and 7 more
- Volunteers
- 320 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Breast Carcinoma, Kidney Carcinoma
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
This study aims to develop objective tools for assessing perceived pain severity in cancer patients and survivors, evaluate the sustained effectiveness of non-pharmacological interventions such as virtual reality in reducing pain…
- Conditions
- Breast Carcinoma, Kidney Carcinoma, Carcinoma
- Trial name
- NCT06456411
- Testing
- Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Renal Carcinoma, Renal Cell Carcinoma
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood…
- Conditions
- Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT06318871
- Testing
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years.
- Trial name
- NCT06623630
- Testing
- Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Kidney Neoplasms, Metastatic Renal Cell Cancer
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the…
- Trial name
- SURF (NCT02689167)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Renal Cell Cancer
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.
- Trial name
- NCT00311467
- Testing
- Capecitabine, Interferon, Interleukin
- Where
- Austria
- Volunteers
- 172 people
- Sponsor
- Central European Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.